SOLIQUA Instructions for use

Update: 30 October, 2023

This product is a combination of insulin glargine and lixisenatide. This product is indicated for the treatment of adults with type 2 diabetes mellitus with inadequate glycemic control, in combination with other oral antihyperglycemic agents, on a background of diet and exercise to improve glycemic control.


File format: PDF

Size: -

MD5 Checksum: 627D1FCA039873D09F2E35981FE60277

Publication date: 30 October, 2023

Downloads: -

PDF Link: SOLIQUA Instructions for use PDF

Also Manuals